H.C. Wainwright more than doubles its price target to $7 as the company delivers its first electrolyzer to a major green hydrogen facility in Portugal.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Analyst sets a new $70 price target, citing strong revenue forecasts and potential for margin expansion for the airline carrier.
Shares surge on massive volume after EPS Ventures announced its intention to acquire LNG shipping firm Cool Company.
A flurry of multi-billion dollar acquisitions by Pfizer, Genmab, and Axcelis signals renewed confidence and strategic positioning in high-growth sectors.
Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.